Sparrow Pharmaceuticals Announces First Patient Enrolled in Phase 2b Clinical Trial Evaluating Clofutriben for Difficult-to-Control Type 2 Diabetes

Sparrow Pharmaceuticals, a targeted cardiometabolic therapeutics company, today announced that the first patient has been ...